S-217622
Sponsors
University Of Minnesota, Shionogi
Conditions
COVID-19Hepatic ImpairmentRenal ImpairmentSARS-CoV-2 Infection
Phase 1
A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants
CompletedNCT05363215
Start: 2022-08-10End: 2023-04-12Updated: 2023-04-24
A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants
CompletedNCT05409911
Start: 2022-09-13End: 2023-04-25Updated: 2023-05-26
Phase 3
A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19
CompletedNCT05305547
Start: 2022-08-03End: 2024-05-24Updated: 2026-08-20
A Multicenter, Adaptive, Randomized, Controlled Trial Platform to Evaluate Safety and Efficacy of Strategies and Treatments for Hospitalized Patients with Respiratory Infections: Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE) - Shionogi Protease Inhibitor (S-217622)
Active, not recruitingCTIS2022-501020-19-01
Start: 2023-07-31Target: 295Updated: 2025-07-16
Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection
CompletedNCT05897541
Start: 2023-06-09End: 2024-09-18Updated: 2026-09-16